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ABSTRACT
Patients with glioblastoma (GBM) have a poor prognosis, 
and inefficient delivery of drugs to tumors represents 
a major therapeutic hurdle. Hematopoietic stem cell 
(HSC)- derived myeloid cells efficiently home to GBM 
and constitute up to 50% of intratumoral cells, making 
them highly appropriate therapeutic delivery vehicles. 
Because myeloid cells are ubiquitously present in the 
body, we recently established a lentiviral vector containing 
matrix metalloproteinase 14 (MMP14) promoter, which 
is active specifically in tumor- infiltrating myeloid cells as 
opposed to myeloid cells in other tissues, and resulted 
in a specific delivery of transgenes to brain metastases 
in HSC gene therapy. Here, we used this novel approach 
to target transforming growth factor beta (TGFβ) as a 
key tumor- promoting factor in GBM. Transplantation of 
HSCs transduced with lentiviral vector expressing green 
fluorescent protein (GFP) into lethally irradiated recipient 
mice was followed by intracranial implantation of GBM 
cells. Tumor- infiltrating HSC progeny was characterized by 
flow cytometry. In therapy studies, mice were transplanted 
with HSCs transduced with lentiviral vector expressing 
soluble TGFβ receptor II–Fc fusion protein under MMP14 
promoter. This TGFβ-blocking therapy was compared 
with the targeted tumor irradiation, the combination of 
the two therapies, and control. Tumor growth and survival 
were quantified (statistical significance determined by 
t- test and log- rank test). T cell memory response was 
probed through a repeated tumor challenge. Myeloid 
cells were the most abundant HSC- derived population 
infiltrating GBM. TGFβ-blocking HSC gene therapy in 
combination with irradiation significantly reduced tumor 
burden as compared with monotherapies and the control, 
and significantly prolonged survival as compared with 
the control and TGFβ-blocking monotherapy. Long- 
term protection from GBM was achieved only with the 
combination treatment (25% of the mice) and was 
accompanied by a significant increase in CD8+ T cells at 
the tumor implantation site following tumor rechallenge. 
We demonstrated a preclinical proof- of- principle for tumor 
myeloid cell- specific HSC gene therapy in GBM. In the 
clinic, HSC gene therapy is being successfully used in non- 
cancerous brain disorders and the feasibility of HSC gene 
therapy in patients with glioma has been demonstrated 
in the context of bone marrow protection. This indicates 
an opportunity for clinical translation of our therapeutic 
approach.
BACKGROUND
There are around 11 700 new primary brain 
tumor cases in the UK every year and the inci-
dence of cases is on the rise. The prognosis is 
worst for patients with glioblastoma (GBM), 
the most aggressive type of brain tumor, with 
an average survival time between 12 and 
18 months.1 The current standard of care 
for patients with GBM includes debulking 
surgery, followed by chemotherapy (temo-
zolomide) and irradiation.2 3
Elevated transforming growth factor beta 
(TGFβ) levels in glioma have been asso-
ciated with high tumor grade and poor 
patient outcomes.4 TGFβ signaling has been 
implicated in invasion, tumor angiogenesis, 
maintenance of GBM stem- like cells and 
immunosuppression.5 6 Various approaches 
targeting TGFβ signaling have been therefore 
investigated preclinically, and several thera-
peutic agents are being tested in clinical trials 
in high- grade brain tumors, including the 
monoclonal antibody fresolimumab, the anti- 
sense oligonucleotide trabedersen, and the 
small molecule inhibitor of TGFβ receptor 
kinase galunisertib.5 6 Current preclinical and 
clinical data suggest that TGFβ blockade is 
likely to be most potent in combination with 
other treatments, including irradiation.7–10
Abnormal and poorly perfused tumor 
vasculature hinders an efficient delivery of 
therapies to the main glioma mass, while 
the blood–brain barrier is likely to hinder 
delivery of therapeutics to cancer cells typi-
cally invading the surrounding tissue.1 3 11 
Thus, new approaches are urgently needed 
for the delivery of therapies to brain tumors. 
In this context, different types of stem cells 
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have been shown to display tumor- homing properties. 
While neuronal and mesenchymal stem cells have been 
extensively studied in preclinical gene therapy targeting 
brain tumors,12 only a few studies have focused on hema-
topoietic stem cells (HSCs).13 14 In the clinic, HSC gene 
therapy has been successfully used in non- cancerous 
brain disorders, including adrenoleukodystrophy.15 16
We have recently demonstrated that the matrix metal-
loproteinase (MMP) 14 promoter drives gene expression 
specifically within the myeloid progeny of HSCs infil-
trating brain metastases in contrast to the myeloid cells 
in other organs.17 Here, we used this promoter in HSC 
gene therapy to deliver TGFβ-blocking peptide to experi-
mental GBM in combination with radiation therapy.
MATERIALS AND METHODS
Cell lines and primary cells
Firefly luciferase (Fluc)- tagged GL261 cells were obtained 
from Covance and HEK293 cells from ATCC. CT- 2A cells 
were kindly provided by Dr David Stojdl and Charles 
Lefebvre (CHEO Research Institute, Ottawa) and stably 
transduced with pFUW- Fluc lentiviral vector.18 Cells were 
cultured in Dulbecco's modified eagle's medium (DMEM) 
containing 10% Fetal bovine serum (FBS), glutamine and 
penicillin/streptomycin. OT- I T cells were isolated from 
Rag1-/- OT- I CD45.1 mice19 and cultured in Iscove modi-
fied dulbecco medium (IMDM; Gibco), 10% FBS, Pen/
Strep, 2 mM glutamine, 50 μM 2- Mercaptoethanol.
Mice
Six to 8- week- old female C57Bl/6J mice were purchased 
from Charles River Laboratories, UK. C57Bl/6- 
Tg(UBCGFP)30Scha/J mice were purchased from 
Jackson Laboratories and bred at the University of Leeds. 
Animals were kept in individually ventilated cages in a 
specific- pathogen- free facility.
Lentiviral expression constructs
The soluble transforming growth factor beta receptor II 
(sTGFβRII) fragment20 fused to a linker region (atatcgg-
ccatggtt) and the mouse Fc chain was gene synthesized 
(Genscript), subcloned into pF- MMP14- GW or pFUGW 
vectors17 using AgeI and EcoRI restriction sites, resulting 
in the pF- MMP14- sTGFβRIIFc and pFUW- sTGFβRIIFc 
lentiviral vectors, respectively. Lentiviral stocks were 
generated and lentiviral titres determined as previously 
described.17
Transduction and transplantation of HSCs
HSCs were isolated from C57Bl/6J mice, transduced with 
lentiviral vectors, and transplanted into recipient mice as 
previously described.17
Intracranial glioma models
GL261/Fluc or CT- 2A/Fluc cells (1×105 in 2 μL basal MEM 
medium) were implanted into mice brains and tumor 
growth was monitored by bioluminescence imaging as 
previously described.17 18 Survival studies were performed 
as previously described.17 One mouse from the control 
group (MMP14:GFP) was excluded from survival analysis 
due to the lack of tumor growth.
Targeted irradiation
Prior to irradiation, mice were randomized based on the 
bioluminescence signal intensity. A fractionated dose of 
5 Gy/day on three consecutive days was delivered using 
a Small Animal Research Radiation Platform (SARRP; 
Xstrahl). After cone beam CT scan, the correct segmenta-
tion was adjusted and the isocenter was aligned to the site 
of injection. The prescription dose selected and a single 
beam with a 3 mm×3 mm collimator was used. Muriplan 
was used to calculate the dose to medium value and 
obtain the irradiation time.
Tissue dissociation and flow cytometry
Brain tumor tissue was enzymatically dissociated as previ-
ously described.17 The following antibodies were used: 
anti- CD45- PECy7 (30- F11; Biolegend), anti- F4/80- AF700 
(CI:A3-1; BioRad), anti- CD11b- V450 (M1/70; BD Biosci-
ence), anti- Gr1- PerCP (RB6- 8C5; Biolegend), anti- Ly6C- 
Viogreen (1G7.G10; Miltenyi), anti- Ly6G- APC (1A8; 
Biolegend), anti- CD3e- APC- Vio770 (REA606; Miltenyi), 
anti- CD8b- PeCy7 (YTS156.7.7; Biolegend), and anti- 
CD4- APC (GK1.5; Miltenyi). The corresponding isotype 
control antibodies were from Biolegend, eBioscience 
or BD Bioscience. Samples were analyzed on LSRII 
(BD Biosciences), Cytoflex S or Cytoflex LX (Beckman 
Coulter) flow cytometers. Flow cytometry data were quan-
tified with FACSDiva or CytExpert V.2.3 software.
Cell transfection and western blot analysis
HEK293 cells were transiently transfected with pFUW- 
sTGFβRIIFc plasmid using Lipofectamine 2000 (Invi-
trogen). Cell lysates and cell culture supernatants 
(collected into serum- free medium for 48 hours) were 
prepared and analyzed by western blot as previously 
described,17 using anti- mouse TGFβ RII primary antibody 
(R&D Systems, AF532) and secondary anti- goat HRP anti-
body (Invitrogen). Anti- actin antibody (Sigma A1978) 
was used as a loading control. Equal cell numbers (for cell 
lysates) and equal volumes (for cell culture supernatants) 
were loaded for all samples.
Inhibition of SMAD phosphorylation by sTGFβRIIFc
OT- I T cells (2×106) isolated from lymph nodes were incu-
bated with 5 ng/mL TGFβ in 1 mL complete medium for 
30 min at 37°C, alone or in the presence of TGFβ inhib-
itor SB431542 (Sigma; 5 μM final concentration), cell 
culture supernatant collected from pFUGW or pFUW- 
sTGFβRIIFc- transfected HEK293 cells. Following fixation 
with 2% paraformaldehyde (PFA) and permeabilization 
with BD phosphoflow Perm buffer III, the mean fluo-
rescence intensity of phospho- SMAD was quantified by 
flow cytometry, using anti- pSMAD2 (S465/467) SMAD3 
(S423/425) rabbit mAb (Cell Signaling; D27F4), followed 
by anti- rabbit- PacificBlue secondary antibody.
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HeLa cells were seeded in 6- well plates at 1.5×105 cells/
well and 48 hours later incubated in cell culture super-
natants collected from pFUGW or pFUW- sTGFβRIIFc- 
transfected HEK293 cells, in the absence or presence of 
5 ng/mL TGFβ for 30 min in a tissue culture incubator 
at 37°C. Cell lysates were analyzed by western blot, using 
anti- pSMAD2 (Ser465/467) rabbit mAb (E8F3R, Cell 
Signaling) followed by anti- rabbit- HRP secondary anti-
body (Invitrogen), and anti- SMAD2/3 (610842, Becton 
Dickinson Transduction Laboratories) mouse anti-
body followed by anti- mouse- HRP secondary antibody 
(Invitrogen).
Taqman qPCR and vector copy number analysis
Isolation of RNA from mouse brain tumor tissue, cDNA 
synthesis, qPCR, isolation of gDNA from mouse bone 
marrow and vector copy number (VCN) analysis were 
performed as previously described.17 The following 
custom Taqman primer/probe reagents were used: 
msTgfbr21_Fwd: (5′-aagagtgcaacgattacatca-3′), msFc1_
Rev: (5′- tcagagtaatggtgagcacat-3′), and FAM- labeled 
Taqman probe (Tgfbr2Fc_1Taqman: 5′-ctgttgatatcggc-
catggttaga-3′). Gapdh (Mm99999915_g1) was from Ther-
moFisher Scientific.
Immunofluorescence and H&E staining
Immunofluorescence on formalin- fixed paraffin- 
embedded tissue (5 μm sections) using heat- mediated 
antigen retrieval with EDTA (pH 8.0), immunofluores-
cence microscopy and image acquisition were performed 
as described.17 Anti- CD45- PE (30- F11; Biolegend) and 
anti- MMP14 (GeneTex) primary antibodies, followed 
by anti- rabbit- Alexa488 (Invitrogen) and anti- rat- Cy3 
(Jackson ImmunoResearch) secondary antibodies were 
used on mouse tissue. Anti- human- CD68 antibody (PG- 
M1; DAKO), and a secondary anti- mouse 488 antibody 
(Invitrogen) were used on human tissue. H&E staining 
was performed using Mayer’s hematoxylin solution and 
eosin Y solution (Sigma).
For quantification of CD68+ cells in human GBM 
samples, the number of total cells based on nuclear 
4',6- diamidino-2- phenylindole (DAPI) stain and the 
number of CD68+ cells were counted in three fields per 
sample.
Statistical analysis
Type of statistical analysis applied is specified in each 
corresponding figure legend. Statistical analysis was 
performed using GraphPad Prism V.8 software.
RESULTS
Accumulation of myeloid cells in GBM
Following their intracranial implantation in C57Bl6 mice, 
firefly luciferase (Fluc)- tagged GL261/Fluc and CT- 2A/
Fluc GBM cells formed large lesions within approximately 
3 weeks (figure 1A–C). A pronounced infiltration of cancer 
cells into the surrounding tissue in CT- 2A model mimicked 
the infiltrative nature of human GBM (figure 1A). Anal-
ysis of tumor- infiltrating immune cells by flow cytometry 
(figure 1D) identified marked infiltration of CD45+ 
hematopoietic cells, amounting to 75.96%±15.72% 
of all cells in GL261 model, and 21.68%±5.33% in the 
CT- 2A model. The predominant cell population were 
CD11b+ myeloid cells (45.95%±7.24% and 7.81%±4.10% 
of all cells in GL261 and CT- 2A models, respectively), 
containing mainly blood- derived macrophages and 
monocytes, and only low levels of microglia, granulocytes, 
and myeloid- derived suppressor cells (below 2% of all 
cells) (figure 1E). T cell infiltration ˂4% was observed in 
both models (figure 1E). Despite differences in myeloid 
cell infiltration between the GL261 and CT2A models, no 
significant difference in survival was detected (median 
survival was 20±6.74 days for GL261, and 17.5±2.25 days for 
CT2A model; figure 1C). In line with previous reports,21 
tumor- infiltrating CD68+ microglia/macrophages could 
also be detected in human patient samples (n=5; 4.3% 
to 16.5% of all cells) (figure 1F). Due to the pronounced 
infiltration of myeloid cells into both mouse and human 
GBM, we reasoned that myeloid cells derived from HSCs 
may be used in cell therapy approaches.
Homing of genetically modified HSC progeny to GBM
To provide a proof- of- principle for lentiviral HSC gene 
therapy targeting GBM, GFP+ murine HSCs isolated 
from transgenic C57Bl/6- Tg(UBCGFP)30Scha/J mice 
were transplanted into lethally irradiated C57Bl6 mice. 
Intracranial tumors were analyzed 3 weeks following the 
intracranial implantation of GL261 and CT- 2A cancer 
cells, respectively (figure 2A). GFP+ cells represented 
62.11%±16.73% (GL261 model) and 19.52%±5.15% 
(CT- 2A model) of all cells within tumors (figure 2B). 
The majority of GFP+ cells were CD45+CD11b+ myeloid 
cells (57.33%±6.53% and 37.43%±16.28% in GL261 and 
CT- 2A models, respectively), consisting mainly of macro-
phages/monocytes, with very low representation of gran-
ulocytes and myeloid derived suppressor cells (below 
3.2%). As expected, microglia were not among GFP+ 
cells, as they are derived from the yolk sac rather than 
HSCs17 22 (figure 2C,D).
Delivery of TGFβ-targeting blocking peptide to GBM in HSCs 
under a myeloid cell-specific gene promoter
We have recently demonstrated that MMP14 is highly 
expressed in the myeloid progeny of HSCs infiltrating 
brain metastases. An ~2 kb MMP14 promoter fragment 
demonstrated specific activity in brain metastases- 
infiltrating myeloid cells as compared with the myeloid 
cells isolated from other tissues, and resulted in a specific 
delivery of therapeutic molecules to brain metastases.17 
We here confirmed that MMP14 is also expressed in hema-
topoietic cells infiltrating syngeneic GBM (figure 3A), 
providing a rationale for using MMP14 promoter frag-
ment to drive the expression of therapeutic genes in 
GBM models.
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Figure 1 Accumulation of myeloid cells in intracranial glioblastoma (GBM). (A) H&E staining of coronal mouse brain sections 
showing tumors generated from GL261 and CT- 2A cancer cells. (B) GL261/Fluc and CT- 2A/Fluc cells (1×105), respectively, 
were implanted intracranially (i.c.) and tumor growth was monitored by bioluminescence imaging (n=10 for GL261; n=5 for 
CT2A). (C) Survival curves for GL261 (n=11) and CT2A (n=6) cancer models. (D) Immune cell infiltration in GL261 and CT- 
2A brain tumors was determined by flow cytometry in mice with engrafted GFP+ hematopoietic stem cells (HSCs) from 
C57Bl/6- Tg(UBCGFP)30Scha/J transgenic mice. Representative contour plots and the gating strategy employed to identify 
macrophages (CD11b+F4/80+Gr1-CD45high) and microglia (CD11b+F4/80+Gr1-CD45low) are shown. (E) Quantification of tumor- 
infiltrating immune cells in GL261 (n=5) and CT- 2A tumors (n=5) by flow cytometry. Hematopoietic cells (CD45+), grouped 
analyzed cell populations (granulocytes, monocytes, macrophages, myeloid- derived suppressor cells (MDSCs), microglia, 
T- cells), macrophages (CD11b+ F4/80+CD45high), microglia (CD11b+F4/80+Gr1-CD45low), T cells (CD45+CD11b-CD3+), MDSCs 
(CD11b+F4/80-Gr1+), granulocytes (CD11b+F4/80-Ly6G+) and monocytes (CD11b+F4/80-Ly6C+) were quantified in mice with 
engrafted GFP+ HSCs from C57Bl/6- Tg(UBCGFP)30Scha/J transgenic mice. Error bars represent SD. (F) Infiltration of CD68+ 
macrophages/microglia in patient GBM tissue as detected by immunofluorescence. Nuclei are stained with DAPI. Scale 
bar, 50 µm. Graph to the right shows the quantification of CD68+ cells in patient GBM tumors (n=5). DAPI, 4',6- diamidino-2- 
phenylindole .
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Figure 2 Homing of genetically modified hematopoietic stem cell (HSC) progeny to glioblastoma. (A) Experimental scheme: 
green fluorescent protein (GFP)- tagged HSCs isolated from C57Bl/6- Tg(UBCGFP)30Scha/J transgenic mice were injected 
intravenously into lethally irradiated C57Bl/6J mice (TBI; total body irradiation). Following bone marrow reconstitution, GL261 
or CT- 2A cancer cells were injected intracranially and immune cell infiltration was assessed by flow cytometry at ~3 weeks 
post- cancer cell injection. (B) The percentage of GFP+ HSC progeny infiltrating brain tumors generated from GL261 (n=5) 
or CT- 2A (n=5) cancer cells was determined by flow cytometry. (C) Representative contour plots and the gating strategy 
employed to identify macrophages (CD11b+F4/80+Gr1-CD45high) and microglia (CD11b+F4/80+Gr1-CD45low) within the GFP+ 
cell population are shown. (D) Quantification of cell populations within GFP+ HSC progeny infiltrating GL261 (n=5) and CT- 2A 
tumors (n=5) by flow cytometry. Hematopoietic cells (CD45+), grouped analyzed cell populations (granulocytes, monocytes, 
macrophages, myeloid- derived suppressor cells (MDSCs), microglia, T cells), macrophages (F4/80+CD11b+CD45high), microglia 
(CD11b+F4/80+Gr1-CD45low), T cells (CD45+CD11b-CD3+), MDSCs (CD11b+F4/80-Gr1+), granulocytes (CD11b+F4/80-Ly6G+) and 
monocytes (CD11b+F4/80-Ly6C+) were quantified. Error bars represent SD.
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Figure 3 Delivery of transforming growth factor beta (TGFβ)- targeting therapy to glioblastoma in hematopoietic stem 
cells (HSCs) under a myeloid cell- specific gene promoter, with and without irradiation (IR) therapy. (A) Expression of matrix 
metalloproteinase 14 (MMP14) in tumor- infiltrating CD45+ hematopoietic cells (white arrows) in intracranial GL261 glioblastoma 
model as determined by immunofluorescence. Levels for the green channel were adjusted using Adobe Photoshop, applying 
equal adjustment to all images. Scale bar: 100 µm. (B) Western blot analysis of sTGFβRIIFc expression in the cell lysate (L) 
and cell culture supernatant (s/n) of HEK293 cells transiently transfected with a lentiviral vector expressing sTGFβRIIFc under 
the Ubiquitin C (UbC) promoter. Untransfected HEK293 cells were used as a control (mock). (C) Quantification of phospho- 
SMAD2/3 mean fluorescence intensity (MFI) in OT- I T cells following stimulation with TGFβ (5 ng/mL) for 30 min, alone or in the 
presence of TGFβ inhibitor SB431542, cell culture supernatant collected from pFUGW- transduced HEK293 cells (SN mock) 
or supernatant collected from the pFUW- sTGFbRIIFc- transduced HEK293 cells (SN sTGFbRIIFc). One representative repeat 
out of 3 is shown. (D) Western blot showing phospho- SMAD2 and total SMAD in HeLa cells following 30 min incubation in cell 
culture supernatants collected from pFUWG or pFUW- sTGFbRIIFc- transduced HEK293 cells (SN mock and SN sTGFbRIIFc, 
respectively), in the presence or absence of TGFβ (5 ng/mL) as indicated. One representative repeat out of 3 is shown. (E) Top: 
experimental scheme: HSCs transduced with a lentiviral construct expressing sTGFβRIIFc under MMP14 promoter fragment 
(MMP14:sTGFβRIIFc) or a control construct expressing GFP under MMP14 promoter fragment (MMP14:GFP) were transplanted 
into lethally irradiated C57Bl6 mice (TBI; total body irradiation). Following bone marrow reconstitution 6 weeks later, GL261 
glioblastoma cells were implanted intracranially. Three doses of IR therapy (5 Gy each) were administered on days 7, 8 and 9 
post- tumor implantation in 2 of the experimental groups. Bottom: a table summarizing experimental groups, with indication 
of average vector copy number (VCN) in the bone marrow (BM; n=4/4/4/7 for control, IR, sTGFβRIIFc, and sTGFβRIIFc+IR 
combination therapy, respectively). (F) Quantification of sTGFβRIIFc expression in brain tumors (BrT) by qPCR. Relative 
expression is shown. (G) Representative bioluminescence images of mice from the four experimental groups as indicated 
(day 17 post- intracranial implantation of cancer cells). (H) Quantification of tumor growth via bioluminescence imaging. The 
signals for each day were normalized to the signals at day 2 post- cancer cell implantation. Error bars represent SD. Statistical 
significance was determined by one- tailed t- test on day 17 (p values as indicated). n=11/11/10/16 for control, IR, sTGFβRIIFc, 
and sTGFβRIIFc+IR combination therapy, respectively (combined data from two independent experiments).
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TGFβ is a major driver of glioma progression.5 6 To 
inhibit TGFβ, we decided to use HSC gene therapy to 
deliver soluble TGFβ decoy receptor fused to the frag-
ment crystallisable IgG (Fc) region (sTGFβRIIFc)20 to 
intracranial GL261 tumors. The expression and secretion 
of sTGFβRIIFc was first confirmed under the Ubiquitin 
C promoter in vitro in HEK293 cells (figure 3B). The 
functionality of the construct was confirmed by demon-
strating an inhibition of TGFβ-induced SMAD2/3 phos-
phorylation in cell culture supernatants collected from 
pFUW- sTGFβRIIFc- transduced as compared with the 
pFUGW- transduced HEK293 cells. This was demon-
strated in OT- I T cells (figure 3C) as well as in HeLa cells 
(figure 3D). sTGFβRIIFc was then cloned downstream 
of our previously characterized MMP14 promoter frag-
ment.17 This vector was used for lentiviral transduction 
of murine HSCs prior to their transplantation into recip-
ient mice (figure 3E). Notably, irradiation (IR) is known 
to increase TGFβ expression in glioma.7 10 This provided 
a rationale to combine the TGFβ blocking therapy with 
localized IR to the tumor, and test it in parallel to the 
respective monotherapies (sTGFβRIIFc and IR) and a 
control group. Mice in IR and control groups received 
HSCs transduced with a lentiviral construct expressing 
GFP downstream of MMP14 promoter (figure 3E).
A successful delivery of sTGFβRIIFc to intracranial 
GBM was confirmed by qPCR (figure 3F). Tumor growth 
was significantly decreased in the combination therapy 
group as compared with the control group (p=0.03), 
sTGFβRIIFc monotherapy (0=0.03) and IR (p=0.04) 
(figure 3G,H). This demonstrated that sTGFβRIIFc can 
be delivered to GBM using HSC gene therapy, and this 
significantly improved the efficacy of IR therapy.
Combined HSC gene therapy targeting TGFβ and IR result in 
long-term protection against intracranial GBM
Survival of mice was monitored to assess long- term bene-
fits of the therapy. Only the combination therapy resulted 
in a significantly longer survival time as compared with 
the control group (p=0.0016; two- tailed log- rank test) 
and TGFβ-blocking monotherapy (p<0.0001; two- tailed 
log- rank test) (figure 4A). Moreover, 25% of the mice 
(4 out of 16) in the combination therapy group demon-
strated long- term survival with a complete tumor rejec-
tion, as compared with only 1 out of 11 mice (9 %) in the 
IR group and 0% in the remaining groups (figure 4A,B). 
At 90 days post- tumor rejection, the surviving mice were 
rechallenged with tumors through intracranial implan-
tation of GL261 cells. While the tumors grew efficiently 
in naïve control mice and in the rechallenged mouse 
from the IR group, the tumors failed to grow in all four 
rechallenged mice from the combination therapy group 
(figure 4C). This demonstrated that in contrast to the 
IR monotherapy, the combination therapy resulted in a 
long- term protection against cancer.
Analysis of immune cells at the tumor implantation site 
at 3 weeks post- intracranial cancer cell injection revealed 
a significantly higher proportion of CD8+ T cells in the 
four mice from the combination therapy group that have 
rejected tumors for the second time, as compared with 
the control mice with successfully growing tumors. In 
contrast, the infiltration of total CD45+ hematopoietic 
cells and CD4+ T cells was similar between the two groups 
(figure 4D,E). This further suggests that, in addition to 
significantly reducing tumor burden and prolonging 
survival, TGFβ-blocking HSC gene therapy in combi-
nation with IR provided a long- term protection against 
cancer through the development of memory T cell 
responses in ¼ of the mice.
DISCUSSION
Lentiviral gene transfer has recently demonstrated 
an excellent safety record, with promising results 
in patients.15 16 The advantage of HSCs over other 
commonly explored stem cell types, such as mesen-
chymal and neuronal stem cells,12 is the ability to isolate 
HSCs in large quantities, and well- established proce-
dures for their therapeutic use. HSC- derived myeloid 
cells, mostly consisting of macrophages, can account for 
over 50% of all cells in GBM,21 23 making them highly 
suitable therapeutic delivery vehicles in this context. As 
myeloid cells are ubiquitously present in the body, we 
here used a vector with MMP14 promoter17 to deliver 
TGFβ-blocking therapy specifically to experimental 
brain tumors, and thereby provided a proof- of- principle 
for the efficacy of HSC gene therapy targeting GBM 
using a tumor myeloid cell- specific gene promoter.
A synergy between IR and TGFβ blockade, using ther-
apeutic approaches other than gene therapy, has been 
previously reported.7–10 In line with this, in our study 
TGFβ-blocking HSC gene therapy combined with IR 
significantly reduced tumor burden as compared with 
monotherapies. Notably, among other suppressive 
effects on the immune system, TGFβ has been shown 
to suppress the cytotoxic function of CD8+ T cells in 
cancer,24 and TGFβ inhibition has been shown to 
enhance tumor elimination by T cells.25 Thus, the effi-
cacy of combined TGFβ blockade and IR in our model 
is likely a combination of direct effects on cancer cells 
and boosting of antitumor immunity.
Durable memory responses against cancer observed 
in ¼ of mice in the combination therapy group in 
our model correlated with a significant increase in 
CD8+ T cells at the tumor implantation site in tumor 
rechallenged mice as compared with naïve mice chal-
lenged with tumors for the first time. In line with this, 
gene expression signatures associated with IFNγ and 
immune- mediated rejection were previously observed 
in breast cancer models treated with IR and antibody- 
mediated TGFβ blockade, but not in monotherapy- 
treated tumors.9 A subsequent clinical study comparing 
two doses of fresolimumab in combination with focal 
radiotherapy to a metastatic site reported a strong 
increase in the CD8+ central memory T cells with a 
higher fresolimumab concentration.8 Thus, it is likely 
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that TGFβ blockade in combination with IR enhances 
both effector T cell function during initial tumor chal-
lenge, as well as long- term memory response.
In the context of TGFβ-blocking therapy in GBM, 
the advantage of our approach is that (1) it overcomes 
the problem of penetration through the blood–brain 
barrier, allowing for an efficient delivery of TGFβ 
blockade with a potential to also reach tissue- invading 
GBM cells; (2) as transgene expression under MMP14 
promoter is restricted to intratumoral myeloid cells,17 
systemic side effects such as keratoacanthomas8 are 
expected to be minimized. Use of tumor- myeloid cell- 
specific rather than general myeloid promoter is also 
important to prevent systemic effects on the immune 
cells; for example, exacerbated colitis with proinflam-
matory cytokine production has been reported in 
a mouse colitis model expressing dominant nega-
tive TGFβRII downstream of a general macrophage 
Figure 4 Hematopoietic stem cell (HSC) gene therapy targeting transforming growth factor beta (TGFβ) in combination with 
irradiation (IR) results in a long- term protection against intracranial glioblastoma. (A) Survival of mice bearing GL261 intracranial 
tumors. The table below the graph shows group sizes at the beginning (day 0) and number of animals at risk (eg, animals that 
are alive) for indicated days. Pooled data from two independent experiments are shown. Statistical significance was determined 
by two- tailed log- rank test. (B) Growth curves for individual tumors as obtained by bioluminescence imaging, displaying total 
flux in photons per second (p/s). (C) Mice that rejected GL261 tumors following the first intracranial implantation of cancer 
cells plus therapy were rechallenged by a second intracranial implantation of GL261 cells at 90 days post- tumor rejection (red 
and green lines). Mice that have received transplantation of MMP14:GFP- transduced HSCs (gray lines) or naïve mice (black 
lines) were implanted with GL261 cells intracranially for the first time and used as controls. Tumor growth was quantified by 
bioluminescence imaging as in (B). (D and E) Representative dot plots showing analysis of CD8+ and CD4+ T cells (D) and 
quantification of immune cells (E) in intracranial tumors (control mice as specified in C) or brain area corresponding to the 
cancer cell implantation site (mice that have rejected tumors for the second time in the combination therapy group) by flow 
cytometry at 3 weeks post- cancer cell implantation. Statistical significance was determined by two- tailed t- test (n=3 and 4, 
respectively, in first and second experiment for control group; n=2 per experiment for rechallenged long- term survivors from the 
combination therapy group).
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promoter.26 Despite the use of our tumor myeloid cell- 
specific promoter, potential off- target toxicities cannot 
be excluded and would need to be closely monitored in 
the context of clinical translation.
The extent of myeloid cell infiltration into glioma 
is variable in patients and this is also reflected in our 
models, with higher percentage of myeloid cells in 
GL261 (~40%) as compared with CT2A tumors (~8%). 
Notably, extent of myeloid cell infiltration in individual 
patients is also expected to have an impact on the ther-
apeutic efficacy, and strategies to enhance myeloid cell 
homing to tumors may be considered.
In our study, we used a strong myeloablative irradia-
tion conditioning to deplete HSCs in the bone marrow 
and make space for the injected genetically modified 
HSCs. For clinical translation, it will be critical to opti-
mize HSC transduction protocols and the conditioning 
regimen, in order to balance a need to achieve ther-
apeutic levels of transgene while minimizing toxicity. 
Busulfan is most commonly used for conditioning in 
the context of autologous HSC gene therapy in genetic 
disorders, and different busulfan doses have been 
used to achieve optimal intensity of conditioning and 
appropriate levels of HSC engraftment tailored to each 
respective disease.27 HSCs have not yet been used in 
the clinic to deliver therapies targeting brain tumors 
directly. However, HSC gene therapy to overexpress 
mutant methylguanine methyltransferase (MGMT) 
has been used for bone marrow chemoprotection 
during temozolomide treatment in combination with 
O6- benzylguanine, the inhibitor of MGMT, to permit 
dose escalation, resulting in surpassing of the median 
survival for patients with GBM with poor prognosis.28 
In this study, conditioning with carmustine resulted in 
successful HSC engraftment. This demonstrates the 
feasibility of applying HSC gene therapy in patients with 
brain tumor and indicates an opportunity for clinical 
translation of our therapeutic approach.
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